Literature DB >> 11106584

The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit.

L Landuzzi1, C De Giovanni, G Nicoletti, I Rossi, C Ricci, A Astolfi, L Scopece, K Scotlandi, M Serra, G P Bagnara, P Nanni, P L Lollini.   

Abstract

Ewing's sarcoma is a primitive highly malignant tumor of bone and soft tissues usually metastasizing to bone, bone marrow, and lung. Growth factor receptors and their ligands may be involved in its growth and dissemination. We analyzed the expression of c-kit and its ligand stem cell factor (SCF) in a panel of six Ewing's sarcoma cell lines. All cell lines exhibited substantial levels of surface c-kit expression, and five of six displayed transmembrane SCF on the cell surface. Expression of c-kit was down-modulated in all lines by exposure to exogenous SCF. The SCF treatment was able to confer to cells a growth advantage in vitro, due both to an increase in cell proliferation and to a reduction in the apoptotic rate. When used in the lower compartment of a migration chamber, SCF acted as a strong chemoattractant for Ewing's sarcoma cells. The pretreatment of cells with SCF reduced their chemotactic response to SCF. In athymic nude mice, Ewing's sarcoma cells injected intravenously metastasized to the lung and to a variety of extrapulmonary sites, including bone and bone marrow. Metastatic sites resembled those observed in Ewing's sarcoma patients and corresponded to SCF-rich microenvironments. The in vitro pretreatment of cells with SCF strongly reduced the metastatic ability of Ewing's sarcoma cells, both to the lung and to extrapulmonary sites. This could be dependent on the down-modulation of c-kit expression observed in SCF-pretreated cells, leading to a reduced sensitivity to the chemotactic and proliferative actions of SCF. Our results indicate that the response to SCF mediated by c-kit may be involved in growth, migration, and metastatic ability of Ewing's sarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106584      PMCID: PMC1885770          DOI: 10.1016/S0002-9440(10)64850-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  Expression of c-kit and kit ligand proteins in normal human tissues.

Authors:  A Lammie; M Drobnjak; W Gerald; A Saad; R Cote; C Cordon-Cardo
Journal:  J Histochem Cytochem       Date:  1994-11       Impact factor: 2.479

2.  Multidrug resistance and malignancy in human osteosarcoma.

Authors:  K Scotlandi; M Serra; G Nicoletti; M Vaccari; M C Manara; G Nini; L Landuzzi; A Colacci; G Bacci; F Bertoni; P Picci; M Campanacci; N Baldini
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

Review 3.  Modulation of the organ microenvironment for treatment of cancer metastasis.

Authors:  I J Fidler
Journal:  J Natl Cancer Inst       Date:  1995-11-01       Impact factor: 13.506

Review 4.  Ewing's sarcoma and peripheral primitive neuroectodermal tumor.

Authors:  H F Jürgens
Journal:  Curr Opin Oncol       Date:  1994-07       Impact factor: 3.645

5.  Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence.

Authors:  A Pagani; R Fischer-Colbrie; U Eder; A Pellin; A Llombart-Bosch; G Bussolati
Journal:  Int J Cancer       Date:  1995-11-27       Impact factor: 7.396

Review 6.  The kit ligand, stem cell factor.

Authors:  S J Galli; K M Zsebo; E N Geissler
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

7.  Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors.

Authors:  D Beck; N Gross; C B Brognara; G Perruisseau
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

8.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.

Authors:  G W Krystal; S J Hines; C P Organ
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

9.  Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form.

Authors:  K Miyazawa; D A Williams; A Gotoh; J Nishimaki; H E Broxmeyer; K Toyama
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

10.  Interleukin 4 down-regulates expression of c-kit and autocrine stem cell factor in human colorectal carcinoma cells.

Authors:  H Lahm; P Amstad; A Yilmaz; Z Borbenyi; J Wyniger; J R Fischer; L Suardet; J C Givel; N Odartchenko
Journal:  Cell Growth Differ       Date:  1995-09
View more
  12 in total

1.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

Review 2.  Ewing tumour: incidence, prognosis and treatment options.

Authors:  M Paulussen; B Fröhlich; H Jürgens
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Authors:  Wessen Maruwge; Pádraig D'Arcy; Annika Folin; Slavica Brnjic; Johan Wejde; Anthony Davis; Fredrik Erlandsson; Jonas Bergh; Bertha Brodin
Journal:  Onco Targets Ther       Date:  2008-11-01       Impact factor: 4.147

4.  The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm.

Authors:  Holly L Spraker; Shawn L Price; Aashi Chaturvedi; Joshua D Schiffman; Kevin B Jones; Stephen L Lessnick; Mary Beckerle; R Lor Randall
Journal:  Front Oncol       Date:  2012-01-16       Impact factor: 6.244

5.  RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells.

Authors:  A Strillacci; C Griffoni; E Spisni; M C Manara; V Tomasi
Journal:  Br J Cancer       Date:  2006-05-08       Impact factor: 7.640

6.  Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours.

Authors:  Y Inagaki; E Hookway; K A Williams; A B Hassan; U Oppermann; Y Tanaka; E Soilleux; N A Athanasou
Journal:  Clin Sarcoma Res       Date:  2016-08-01

Review 7.  Potential approaches to the treatment of Ewing's sarcoma.

Authors:  Hongjiu Yu; Yonggui Ge; Lianying Guo; Lin Huang
Journal:  Oncotarget       Date:  2017-01-17

Review 8.  CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.

Authors:  Brittni M Foster; Danish Zaidi; Tyler R Young; Mary E Mobley; Bethany A Kerr
Journal:  Biomedicines       Date:  2018-03-08

Review 9.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.

Authors:  Limin Zhu; Madonna M McManus; Dennis P M Hughes
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

10.  Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications.

Authors:  Ana Teresa Amaral; Maria Cristina Manara; Dagmar Berghuis; José Luis Ordóñez; Michele Biscuola; Maria Angeles Lopez-García; Daniel Osuna; Enrico Lucarelli; Francesco Alviano; Arjan Lankester; Katia Scotlandi; Enrique de Álava
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.